Organovo Holdings (ONVO) vs. Its Rivals Head to Head Review

Organovo Holdings (NASDAQ: ONVO) is one of 213 publicly-traded companies in the “Biotechnology & Medical Research” industry, but how does it weigh in compared to its competitors? We will compare Organovo Holdings to similar companies based on the strength of its analyst recommendations, risk, dividends, valuation, profitability, earnings and institutional ownership.

Insider & Institutional Ownership

23.9% of Organovo Holdings shares are owned by institutional investors. Comparatively, 46.5% of shares of all “Biotechnology & Medical Research” companies are owned by institutional investors. 10.2% of Organovo Holdings shares are owned by company insiders. Comparatively, 13.9% of shares of all “Biotechnology & Medical Research” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Risk and Volatility

Organovo Holdings has a beta of 3.13, suggesting that its share price is 213% more volatile than the S&P 500. Comparatively, Organovo Holdings’ competitors have a beta of 1.53, suggesting that their average share price is 53% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Organovo Holdings and its competitors, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Organovo Holdings 0 0 4 0 3.00
Organovo Holdings Competitors 490 2383 6475 122 2.66

Organovo Holdings currently has a consensus target price of $6.94, indicating a potential upside of 344.71%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 14.45%. Given Organovo Holdings’ stronger consensus rating and higher possible upside, equities analysts plainly believe Organovo Holdings is more favorable than its competitors.

Valuation and Earnings

This table compares Organovo Holdings and its competitors gross revenue, earnings per share (EPS) and valuation.

Gross Revenue NetIncome Price/Earnings Ratio
Organovo Holdings $4.23 million -$38.44 million -4.00
Organovo Holdings Competitors $220.75 million -$39.68 million -59.50

Organovo Holdings’ competitors have higher revenue, but lower earnings than Organovo Holdings. Organovo Holdings is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.


This table compares Organovo Holdings and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Organovo Holdings -918.97% -65.49% -60.15%
Organovo Holdings Competitors -3,960.65% -119.05% -43.96%


Organovo Holdings beats its competitors on 7 of the 12 factors compared.

About Organovo Holdings

Organovo Holdings, Inc. is an early commercial-stage company focused on developing and commercializing functional human tissues. The Company focuses on the generation of three-dimensional (3D) human tissues, by utilizing its platform technology to create human tissue constructs in 3D. It is focused on development of products, including 3D human tissues used for the preclinical assessment of drug effects, including applications in predictive toxicology, absorption, distribution, metabolism, excretion (ADME), and drug metabolism and pharmacokinetics (DMPK); customized human tissues as living, dynamic models of human biology or disease, for use in drug discovery and development, and three-dimensional human tissues for clinical applications, such as blood vessels for bypass grafting, nerve grafts for nerve damage repair and functional tissue patches for the repair or replacement of damaged tissues and organs.

What are top analysts saying about Organovo Holdings Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Organovo Holdings Inc. and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit